New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,355.42 3.77 +0.28%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Revenue to profit Fiscal 2025, year to Dec 31, 2025

Of every $100 of revenue, $31.67 was left as profit. Gross margin has risen four years running, from 74.2% to 83.0%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue65.2100.0%
Cost of revenue−11.1−17.0%
Gross profit54.183.0%
Research & development−13.3−20.5%
Selling, general & admin−11.1−17.0%
Other operating costs−3.4−5.2%
Operating income26.340.4%
Other income, net−0.6−0.9%
Income tax−5.1−7.8%
Net income20.631.7%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue$21.2B$20.0B$21.5B$22.3B$24.5B$28.3B$28.5B$34.1B$45.0B$65.2B
Operating income$3.3B$2.0B$3.5B$5.0B$6.1B$6.4B$7.1B$6.5B$12.9B$26.3B
Net income$2.7B−$204M$3.2B$8.3B$6.2B$5.6B$6.2B$5.2B$10.6B$20.6B
Net margin (right axis)12.9%−1.0%15.0%37.3%25.2%19.7%21.9%15.4%23.5%31.7%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
65,179.00 45,043.00 34,124.00 28,541.40 28,318.40 24,539.80 22,319.50 21,493.30 19,973.80 21,222.10
Revenue Growth
44.70% 32.00% 19.56% 0.79% 15.40% 9.95% 3.84% 7.61% (5.88%) 6.33%
Gross Profit
54,127.00 36,625.00 27,042.00 21,911.60 21,005.60 19,056.50 17,598.30 16,811.60 15,526.10 15,512.00
Operating Income
26,302.00 12,899.00 6,457.00 7,127.30 6,357.10 6,058.00 4,974.30 3,534.50 2,003.30 3,261.20
EBT
25,731.00 12,680.00 6,554.00 6,806.40 6,155.50 7,229.90 5,265.90 3,680.10 2,304.80 3,374.00
Income after Tax
20,640.00 10,590.00 5,240.00 6,244.80 5,581.70 6,193.70 4,637.90 3,150.60 (86.40) 2,737.60
Net Income Common
20,640.00 10,590.00 5,240.00 6,244.80 5,581.70 6,193.70 8,318.40 3,232.00 (204.10) 2,737.60
EPS (Diluted)
22.95 11.71 5.80 6.90 6.12 6.79 8.89 3.13 (0.19) 2.58
Shares (Diluted, Weighted)
899.30 904.10 903.30 904.62 911.68 912.51 935.68 1,033.67 1,052.02 1,061.83
Gross Margin
83.04% 81.31% 79.25% 76.77% 74.18% 77.66% 78.85% 78.22% 77.73% 73.09%
EBIT Margin
40.35% 28.64% 18.92% 24.97% 22.45% 24.69% 22.29% 16.44% 10.03% 15.37%
Net Profit Margin
31.67% 23.51% 15.36% 21.88% 19.71% 25.24% 37.27% 15.04% (1.02%) 12.90%
Free Cash Flow Margin
13.77% 8.35% 2.32% 20.08% 21.39% 20.83% 17.04% 20.07% 22.72% 18.32%
EBITDA
28,299.00 14,666.00 7,984.00 8,649.80 7,904.70 7,381.90 6,206.90 5,143.50 3,570.60 4,757.80
EBIT
26,302.00 12,899.00 6,457.00 7,127.30 6,357.10 6,058.00 4,974.30 3,534.50 2,003.30 3,261.20

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026